Literature DB >> 17252242

Does cigarette smoking increase plasma urotensin II concentrations?

S J Gold1, J P Thompson, J P Williams, E E F Helm, J Sadler, W Song, L L Ng, D G Lambert.   

Abstract

OBJECTIVE: Human urotensin II (UII) acts on the urotensin (UT) receptor and is the most potent mammalian vasoconstrictor identified to date. The role of UII in human cardiovascular regulation remains unclear, and the results of plasma measurements have been conflicting, perhaps because different measurement techniques have been used. The effects of cigarette smoking on plasma UII concentrations are unknown. The primary aim of our study was to demonstrate whether cigarette smoking had any effect on plasma UII concentrations in otherwise healthy volunteers. Our secondary aim was to compare the results obtained from assaying simultaneously using both radioimmunoassay (RIA) and immunoluminometric assay (ILMA).
METHODS: Blood was taken from 20 healthy male non-smokers and 20 healthy male cigarette smokers. Plasma was separated and stored at -70 degrees C. Samples were batch analysed simultaneously for UII using RIA and ILMA.
RESULTS: Median (range) plasma UII concentrations were lower in non-smokers [1.67 (1.0-2.27) pg ml(-1)] compared to smokers [2.62 (1.87-3.46) pg ml(-1)] (P = 0.03) measured using RIA. Those who had smoked a cigarette in the 10 min before sampling had greater concentrations of UII [3.10 (1.87-4.60) pg ml(-1)] compared to controls (P = 0.01). Plasma UII concentrations determined by ILMA were consistently low with no differences between groups.
CONCLUSION: The data obtained by RIA show that smoking may increase plasma concentrations of UII with a more pronounced increase when a cigarette has been smoked recently. There was a complete lack of correlation between RIA and ILMA for the whole data set, which suggests that some of the variability in plasma UII reported in the literature may result from differences between assays.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17252242     DOI: 10.1007/s00228-006-0252-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  31 in total

Review 1.  Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addiction.

Authors:  N L Benowitz
Journal:  N Engl J Med       Date:  1988-11-17       Impact factor: 91.245

2.  Effect of exogenous urotensin-II on vascular tone in skin microcirculation of patients with essential hypertension.

Authors:  Brigitte Sondermeijer; Andrew Kompa; Paul Komesaroff; Henry Krum
Journal:  Am J Hypertens       Date:  2005-09       Impact factor: 2.689

3.  Non-competitive immunochemiluminometric assay for cardiotrophin-1 detects elevated plasma levels in human heart failure.

Authors:  Leong L Ng; Russell J O'Brien; Bettina Demme; Sonja Jennings
Journal:  Clin Sci (Lond)       Date:  2002-04       Impact factor: 6.124

4.  A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts.

Authors:  H A Bern; K Lederis
Journal:  J Endocrinol       Date:  1969-09       Impact factor: 4.286

5.  Effects of pre-eclampsia on maternal plasma, cerebrospinal fluid, and umbilical cord urotensin II concentrations: a pilot study.

Authors:  E Cowley; J P Thompson; P Sharpe; J Waugh; N Ali; D G Lambert
Journal:  Br J Anaesth       Date:  2005-08-26       Impact factor: 9.166

6.  Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

7.  Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

Authors:  Y Katano; A Ishihata; T Aita; T Ogaki; T Horie
Journal:  Eur J Pharmacol       Date:  2000-08-18       Impact factor: 4.432

Review 8.  Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease.

Authors:  S A Douglas; E H Ohlstein
Journal:  Trends Cardiovasc Med       Date:  2000-08       Impact factor: 6.677

Review 9.  Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.

Authors:  Richard E Gilbert; Stephen A Douglas; Henry Krum
Journal:  Curr Opin Investig Drugs       Date:  2004-03

Review 10.  Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain.

Authors:  Masaaki Mori; Masahiko Fujino
Journal:  Peptides       Date:  2004-10       Impact factor: 3.750

View more
  1 in total

Review 1.  Urotensin II in cardiovascular regulation.

Authors:  Fraser D Russell
Journal:  Vasc Health Risk Manag       Date:  2008
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.